
Regeneron didn't want to 'bid against itself' in Checkmate deal as five global pharmas declined to counteroffer
Checkmate Pharmaceuticals knew time was running out to fund the future of its sole asset. The cash reserves at Art Krieg’s I/O biotech would run out as the clock struck 2023, and it didn’t help that Checkmate had struggled to attract institutional investor interest in 2021 and again couldn’t eke out any semblance of acquisition appetite from five “global pharmaceutical companies.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.